-+ 0.00%
-+ 0.00%
-+ 0.00%

*Cybin: Phase 2 GAD Study Enrolled 36 Participants to Evaluate Safety and Efficacy of CYB004 at 12 Weeks After First Dose >CYBN

Dow Jones·09/08/2025 11:33:00

Please log in to view news